Find an expert

Critical Care Medicine focuses on supporting patients, often with one or multiple organ failures. Based at the largest Australian cardiac hospital, our research investigates better ways to support patients with heart and/or lung failure. We explore technological, pharmacological and engineering advances that could help our patients to live longer and better. Our group is world-renowned for clinically relevant large animal models, including heart failure, respiratory failure (ARDS), heart transplantation, sepsis, cardiogenic shock, and more. All our studies use hospital-grade equipment and follow the same clinical guideline to maximise translation. We actively take on honours, MPhil and PhD students from multi-disciplinary backgrounds (science, engineering, medicine, allied health), with a successful track record in supporting our students to secure their own grants and funding. Students are expected to contribute to other studies of the group. For more information about the group, please visit ccrg.org.au, and email if you are interested to join us.

Professor Rachel Thomson is a Head of the Greenslopes Clinical Unit, Thoracic Physician and clinical researcher working at Greenslopes Private Hospital.

She has an international reputation in the area of Pulmonary Nontuberculous mycobacterial disease. She has published widely in the area and is regularly invited to speak at international and national meetings.https://medical-school.uq.edu.au/research/ntm-research-group

Her current research focuses on immunological and environmental aspects of susceptibility to NTM infection, characteristics of the lung and gut microbiome in NTM, and improving treatment outcomes.

In a clinical capacity, Professor Thomson is able to offer patients expert management of their disease at Pulmedica, Greenslopes Private Hospital, at public clinics at The Prince Charles Hospital and the MetroSouth Clinical TB service of the Princess Alexandra Hospital and via telehealth for patients across Australia. Patients can also access novel treatments through clinical trials in both the private and public sector.

Prof Thomson also has a special interest in respiratory problems of the elite athlete. This includes asthma management, vocal cord dysfunction, and the requirements of national and international doping organisations for asthma medications.

Dr Ran Wang graduated with her PhD in 2015, and after undertaking a postdoc position in Scripps Research, USA returned to Australia in 2017. She is now a Senior Postdoctoral Researcher supported by the prestigious Bushell Postdoctoral Research Fellowship from the Gastroenterology Society of Australia. Dr Wang is interested to understand the nature of inflammation in gut and lung and investigate the local and systemic impacts of chronic gut inflammation. In addition to a growing track-record in the mucosal immunology field, she is also building an inter-disciplinary research profile in material science and nanotechnology for drug delivery and immune modulation. She is the Associate Editor of Frontier of Cellular and Infection Microbiology Journal since 2018.

Dr. Ayaho Yamamoto is the Group Leader of Laboratory Science at the Children's Health and Environmental Program and is a research fellow in the field of Biomedical Science. Her research focuses on understanding the mechanistic links between environmental exposures and adverse respiratory outcomes. In particular, she focuses on the cellular responses following air pollution exposure and/or viral infection on human respiratory epithelium, and the age differences in immune defence mechanisms. Investigate on early intervention strategies with dietary antioxidants to improve respiratory health and reduce the risk of long-term chronic diseases.

Dr. Yamamoto has a Bachelor of Science in Environmental Health and Public Health; her research focused on childhood asthma. She has a Master of Science in Biomedical Science and Pharmacology; the research focus was to understand the mechanisms and to test new drugs for osteoporosis and chondrosarcomas metastasis. She has worked in a Uni-based start-up company for drug development.